Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/37534
Title: | Examining maintenance care following infliximab salvage therapy for acute severe ulcerative colitis. | Authors: | Hebbard G.;Moore G. ;De Cruz P.;Seah D.;Choy M.C.;Gorelik A.;Connell W.R.;Sparrow M.P.;Van Langenberg D. | Institution: | (Seah, Choy, De Cruz) Department of Gastroenterology, Austin Health, Melbourne, Australia (Choy, Connell) Department of Gastroenterology, St Vincent's Hospital Melbourne, Melbourne, Australia (Choy, De Cruz) Department of Medicine, Austin Academic Centre, University of Melbourne, Melbourne, Australia (Gorelik) Melbourne EpiCentre, Melbourne Health, Melbourne, Australia (Sparrow) Department of Gastroenterology, Alfred Health, Melbourne, Australia (Van Langenberg) Department of Gastroenterology, Eastern Health, Melbourne, Australia (Hebbard) Department of Gastroenterology, Melbourne Health, Melbourne, Australia (Moore) Department of Gastroenterology, Monash Health, Melbourne, Australia (Sparrow, Van Langenberg, Moore) Department of Medicine, Monash University, Melbourne, Australia | Issue Date: | 5-Jan-2018 | Copyright year: | 2018 | Publisher: | Blackwell Publishing | Place of publication: | Australia | Publication information: | Journal of Gastroenterology and Hepatology (Australia). 33 (1) (pp 226-231), 2018. Date of Publication: January 2018. | Journal: | Journal of Gastroenterology and Hepatology | Abstract: | Background and Aim: Data supporting the optimal maintenance drug therapy and strategy to monitor ongoing response following successful infliximab (IFX) induction, for acute severe ulcerative colitis (ASUC), are limited. We aimed to evaluate maintenance and monitoring strategies employed in patients post-IFX induction therapy. Method(s): Patients in six Australian tertiary centers treated with IFX for steroid-refractory ASUC between April 2014 and May 2015 were identified via hospital IBD and pharmacy databases. Patients were followed up for 1 year with clinical data over 12 months recorded. Analysis was limited to patient outcomes beyond 3 months. Result(s): Forty one patients were identified. Five of the 41 (12%) patients underwent colectomy within 3 months, and one patient was lost to follow-up. Six of 35 (17%) of the remaining patients progressed to colectomy by 12 months. Maintenance therapy: Patients maintained on thiopurine monotherapy (14/35) versus IFX/thiopurine therapy (15/35) were followed up. Two of 15 (13%) patients who received combination maintenance therapy underwent a colectomy at 12 months, compared with 1/14 (7%) patients receiving thiopurine monotherapy (P = 0.610). Monitoring during maintenance: Post-discharge, thiopurine metabolites were monitored in 15/27 (56%); fecal calprotectin in 11/32 (34%); and serum IFX levels in 4/20 (20%). Twenty of 32 (63%) patients had an endoscopic evaluation after IFX salvage with median time to first endoscopy of 109 days (interquartile range 113-230). Conclusion(s): Following IFX induction therapy for ASUC, the uptake of maintenance therapy in this cohort and strategies to monitor ongoing response were variable. These data suggest that the optimal maintenance and monitoring strategy post-IFX salvage therapy remains to be defined.Copyright © 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/jgh.13850 | ORCID: | Choy, Matthew C; ORCID: http://orcid.org/0000-0001-5206-0097 Van Langenberg, Daniel; ORCID: http://orcid.org/0000-0003-3662-6307 | Link to associated publication: | Click here for full text options | PubMed URL: | 28618062 [http://www.ncbi.nlm.nih.gov/pubmed/?term=28618062] | ISSN: | 0815-9319 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/37534 | Type: | Article | Subjects: | patient monitoring priority journal rash/si [Side Effect] remission sigmoidoscopy topical treatment treatment outcome *ulcerative colitis/dt [Drug Therapy] *ulcerative colitis/su [Surgery] ulcerative colitis/dt [Drug Therapy] albumin/ec [Endogenous Compound] C reactive protein/ec [Endogenous Compound] calgranulin/ec [Endogenous Compound] drug metabolite *infliximab/ae [Adverse Drug Reaction] *infliximab/cb [Drug Combination] *infliximab/cr [Drug Concentration] *infliximab/dt [Drug Therapy] mercaptopurine/cb [Drug Combination] mercaptopurine/dt [Drug Therapy] mesalazine/dt [Drug Therapy] methotrexate/cb [Drug Combination] methotrexate/dt [Drug Therapy] tacrolimus/cb [Drug Combination] tacrolimus/dt [Drug Therapy] *salvage therapy male acute cholecystitis/si [Side Effect] *acute disease/dt [Drug Therapy] *acute disease/su [Surgery] acute disease/dt [Drug Therapy] adult article Australia clinical article colon resection controlled study disease duration drug blood level female follow up hospital admission hospitalization human maintenance therapy monotherapy outcome assessment hospitalization human maintenance therapy male monotherapy outcome assessment patient monitoring priority journal rash / side effect remission *salvage therapy sigmoidoscopy topical treatment treatment outcome *ulcerative colitis / *drug therapy / *surgery ulcerative colitis / drug therapy adult Article *acute disease / *drug therapy / *surgery acute cholecystitis / side effect acute disease / drug therapy Australia clinical article colon resection controlled study disease duration drug blood level female follow up hospital admission |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.